Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-25 @ 7:06 PM
Study NCT ID:
NCT05583604
Status:
AVAILABLE
Last Update Posted:
2025-12-18
First Post:
2022-10-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Managed Access Programs for AIN457, Secukinumab
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Overview
Official Title:
Managed Access Programs for AIN457, Secukinumab
Status:
AVAILABLE
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
Detailed Description:
CAIN457M2002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CAIN457M2002M to provide access to Secukinumab for adult and adolescent patients with Hidradenitis Suppurativa (HS)
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: